KUALA LUMPUR, September 19 – Ramsay Sime Darby Health Care (RSDH) has entered into a collaboration with Mayo Clinic Laboratories, the global reference laboratory of Mayo Clinic, to offer specialized laboratory services to its patients. Subang Jaya Medical Centre (SJMC), as the flagship hospital under RSDH, will serve as the centralized referral hub for laboratory tests across all RSDH hospitals. This partnership is aimed at providing patients with access to specialized tests, thereby enhancing diagnostic capabilities within the Malaysian healthcare system.
Under this reference laboratory service agreement, SJMC will send selected specialized tests, including neurology, hematology, and oncology evaluations, to Mayo Clinic Laboratories in Rochester, Minnesota, United States. This aligns with the core focus areas of RSDH hospitals and complements their Centers of Excellence. These tests play a pivotal role in accurate disease diagnosis. By leveraging the expertise and advanced technology of Mayo Clinic Laboratories, SJMC aims to ensure the most precise and effective treatment plans possible for patients.
Peter Hong, Group Chief Executive Officer of RSDH, expressed enthusiasm, stating, “We are delighted to establish this reference laboratory service agreement with Mayo Clinic Laboratories, driven by our shared objective of advancing healthcare knowledge and expertise. By tapping into their knowledge, we can provide our patients access to specialized tests that were previously unavailable in our region. Undoubtedly, this represents a significant leap forward in enhancing patient care and outcomes, reaffirming our commitment to delivering high-quality healthcare services.”
Bryan Lin, Chief Executive Officer of SJMC, highlighted the mutual benefits of this collaboration, saying, “Working with Mayo Clinic Laboratories opens up new possibilities for precise diagnosis, enabling our doctors to offer tailored treatment options, thus improving patient outcomes. As a flagship hospital for Malaysia Healthcare Travel Council (MHTC), we believe that this agreement will help strengthen trust in our clinical outcomes.”
